Skip to main content

Galapagos Extends by $1M siRNA-Based Target-Validation Deal With Cystic Fibrosis Foundation

NEW YORK (GenomeWeb News) — Galapagos has extended by 15 months and €800,000 ($1 million) a two-year agreement with Cystic Fibrosis Foundation Therapeutics to use its siRNA and cDNA collections to develop new treatments for cystic fibrosis, the company said today.
 
Galapagos said its BioFocus DPI division is using its SilenceSelect adenoviral library to design assays that can identify and validate potential targets that could be the “basis for the development of new medicines.”   
 
Galapagos signed the original two-year, €1.3-million research agreement with CFFT, a drug development affiliate of the Cystic Fibrosis Foundation, in April 2005.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.